No Data
Shionogi & Co. GAAP EPS of ¥115.13, revenue of ¥71.84B
Shionogi & Co. press release (OTCPK:SGIOF): Q1 GAAP EPS of ¥115.13. Revenue of ¥71.84B (+4.2% Y/Y).
ViiV Healthcare announces data from unblinded phase of HPTN 084 study
ViiV Healthcare, the global specialist HIV company majority-owned by GSK (GSK), with Pfizer (PFE) and Shionogi (SIOGY) as shareholders, announced new efficacy and safety findings from the unblinded pe
Shionogi faces setback for COVID pill as Japan delays authorization again
A group of health experts in Japanese health ministry delayed emergency approval on Wednesday for the COVID-19 pill developed by Osaka-based drugmaker Shionogi & Co. (OTCPK:SGIOF) (OTCPK:SGIOY) ci
Nikkei 225 Up 0.5% on Boost From Retail, Tech Sectors
05:54 AM EDT, 07/15/2022 (MT Newswires) -- The Nikkei 225 opened higher, wobbled, but finished up 0.5% after a profit forecast from index-heavyweight Fast Retailing (FRCOF, 9983:Tokyo) boosted the ret
Shionogi says oral COVID-19 therapy rapidly cleared virus in mid-stage trial
Announcing new Phase 2b results for the company's experimental COVID-19 therapy, S-217622, Japanese drugmaker Shionogi & Co. (OTCPK:SGIOY) (OTCPK:SGIOF) said that the once-daily oral treatment led
Pfizer set to add nearly $24 billion revenue with COVID-19 pill - Airfinity
Paxlovid, the COVID-19 pill developed by Pfizer (NYSE:PFE), is set to generate $23.6 billion in revenue in 2022 to become one of the fastest-selling treatments of all time, London-based data analytics
Nikkei 225 Declines 1.6% on Federal Reserve Outlook
06:02 AM EDT, 04/22/2022 (MT Newswires) -- The Nikkei 225 opened lower Friday on overnight Wall Street cues and drifted sideways, finishing down 1.6% as traders weighed the outlook for a tighter polic
Ascletis ASC11 preclinical data shows promise as potential therapy for COVID-19
Ascletis Pharma (OTCPK:ASCLF) said data from antiviral cellular assays suggested that its drug ASC11 showed potential to be effective treatment for COVID-19. The Chinese company said that in antivira
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J, ViiV Co-developed Long-Acting HIV Treatment Gets FDA Approval For Treating Adolescents Johnso
Nikkei 225 Up 0.1% On Lack of Cues, Dividend Buys
05:52 AM EDT, 03/25/2022 (MT Newswires) -- The Nikkei 225 opened evenly and traded narrowly on Friday, finishing up 0.1% as traders awaited fresh catalysts and bought issues to lock in rights before e
Loading...